Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford Immunotec has reported encouraging results from a recent study, which demonstrated a decline in the positivity of T-SPOT.TB test in subjects who had been taking anti-TB therapy for a longer length of time.
Subscribe to our email newsletter
The study investigated the response of the T-SPOT.TB assay in 33 subjects with culture confirmed TB. T-SPOT.TB was positive in 83% of the subjects who had received less than four months anti-TB therapy whereas only 17% of subjects who had received more than four months therapy were positive by the test. These findings suggest that the response of T-SPOT.TB declines with therapy and may be a potentially useful treatment monitoring tool.
Peter Wrighton-Smith, CEO of Oxford Immunotec, said: “This study provides additional evidence that the T-SPOT.TB test may have a future role to play as an additional tool in the monitoring of anti-TB treatments. Treatment monitoring in TB infection is particularly important since the treatment period is typically six months or longer.”